Macquarie Group’s Altimmune ALT Stock Holding History

Macquarie Group’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100,000	Closed	-$377K	–	876
2025 Q3	$377K	Hold	100,000	–	–	﹤0.01%	1438
2025 Q2	$387K	Hold	100,000	–	–	﹤0.01%	1491
2025 Q1	$500K	Hold	100,000	–	–	﹤0.01%	1476
2024 Q4	$721K	Hold	100,000	–	–	﹤0.01%	1398
2024 Q3	$614K	Hold	100,000	–	–	﹤0.01%	1447
2024 Q2	$665K	Buy	100,000 +55,526	+125%	+$410K	﹤0.01%	1438
2024 Q1	$453K	Buy	+44,474	New	+$452K	﹤0.01%	1454
2023 Q1	–	Sell	-208,685	Closed	-$3.43M	–	1708
2022 Q4	$3.43M	Buy	+208,685	New	+$2.34M	﹤0.01%	1050
2018 Q4	–	Sell	-3,101	Closed	-$14K	–	2241
2018 Q3	$14K	Sell	3,101 -5,696	-65%	-$62K	﹤0.01%	1954
2018 Q2	$117K	Buy	8,797 +1,767	+25%	+$34.8K	﹤0.01%	1806
2018 Q1	$245K	Buy	7,030 +6,097	+653%	+$306K	﹤0.01%	1641
2017 Q4	$56K	Buy	+933	New	+$59.6K	﹤0.01%	1982

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Macquarie Group's ALT Position: Q4 2025 in Review

Macquarie Group sold out of Altimmune (ALT) in Q4 2025, closing a stake of 100,000 shares — an estimated $377K sold.

Macquarie Group first reported a position in ALT in Q4 2017 and held it in 12 quarters. The position peaked at $3.43M in Q4 2022. 181 funds tracked by Wall St. Rank hold ALT as of Q4 2025.

Macquarie Group reported no remaining Altimmune position as of Q4 2025 after selling out during the quarter.
Macquarie Group sold 100,000 Altimmune shares in Q4 2025, an estimated $377K.
Macquarie Group first reported a position in Altimmune in Q4 2017 and held it in 12 quarters.
Macquarie Group's Altimmune position peaked at $3.43M in Q4 2022.
181 funds tracked by Wall St. Rank held Altimmune as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.